GR3020517T3 - Human erythropoietin muteins, their production and their use - Google Patents

Human erythropoietin muteins, their production and their use

Info

Publication number
GR3020517T3
GR3020517T3 GR960401877T GR960401877T GR3020517T3 GR 3020517 T3 GR3020517 T3 GR 3020517T3 GR 960401877 T GR960401877 T GR 960401877T GR 960401877 T GR960401877 T GR 960401877T GR 3020517 T3 GR3020517 T3 GR 3020517T3
Authority
GR
Greece
Prior art keywords
production
human erythropoietin
muteins
erythropoietin muteins
epo
Prior art date
Application number
GR960401877T
Other languages
English (en)
Inventor
Mathias Dr Fibi
Gerd Dr Zettlmeissl
Hans Dr Kuepper
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of GR3020517T3 publication Critical patent/GR3020517T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR960401877T 1989-07-20 1996-07-11 Human erythropoietin muteins, their production and their use GR3020517T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3923963A DE3923963A1 (de) 1989-07-20 1989-07-20 Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Publications (1)

Publication Number Publication Date
GR3020517T3 true GR3020517T3 (en) 1996-10-31

Family

ID=6385421

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960401877T GR3020517T3 (en) 1989-07-20 1996-07-11 Human erythropoietin muteins, their production and their use

Country Status (13)

Country Link
US (1) US5457089A (el)
EP (1) EP0409113B1 (el)
JP (1) JP3062583B2 (el)
KR (1) KR0183981B1 (el)
AT (1) ATE139261T1 (el)
AU (1) AU638470B2 (el)
CA (1) CA2021528C (el)
DE (2) DE3923963A1 (el)
DK (1) DK0409113T3 (el)
ES (1) ES2090061T3 (el)
GR (1) GR3020517T3 (el)
IE (1) IE902643A1 (el)
PT (1) PT94761B (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646822B2 (en) * 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994002611A2 (en) * 1992-07-28 1994-02-03 New England Deaconess Hospital Recombinant human erythropoietin with altered biological activity
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
CN1125401A (zh) * 1993-04-29 1996-06-26 艾博特公司 促红细胞生成素类似物组合物和方法
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
DE69726571T2 (de) * 1997-09-01 2004-11-04 Aventis Pharma Deutschland Gmbh Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
US6506595B2 (en) * 1998-03-31 2003-01-14 Itoham Foods Inc. DNAs encoding new fusion proteins and processes for preparing useful polypeptides through expression of the DNAs
WO1999054486A1 (en) * 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
CN100338091C (zh) * 1999-09-25 2007-09-19 伊藤火腿株式会社 编码新的融合蛋白的dna和通过该dna的表达来制备有用的多肽的方法
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE500838T1 (de) * 2000-09-08 2011-03-15 Amylin Pharmaceuticals Inc ßPSEUDOß-NATIVE CHEMISCHE LIGATION
WO2002024899A2 (en) 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
DE602004027483D1 (de) * 2003-05-23 2010-07-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
KR100632985B1 (ko) * 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
EP1673102A1 (en) * 2003-10-17 2006-06-28 Crucell Holland B.V. Treatment and prevention of decubitus
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP1966237A2 (en) * 2005-11-24 2008-09-10 Laboratoires Serono SA Erythropoietin polypeptides and uses thereof
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
KR100700039B1 (ko) * 2007-01-31 2007-03-26 이수왕 음료용 병
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition

Also Published As

Publication number Publication date
PT94761A (pt) 1991-03-20
DK0409113T3 (da) 1996-10-07
KR0183981B1 (ko) 1999-04-01
EP0409113B1 (de) 1996-06-12
CA2021528A1 (en) 1991-01-21
US5457089A (en) 1995-10-10
PT94761B (pt) 1997-03-31
AU5914590A (en) 1991-01-24
KR910003102A (ko) 1991-02-26
DE59010367D1 (de) 1996-07-18
JP3062583B2 (ja) 2000-07-10
ATE139261T1 (de) 1996-06-15
IE902643A1 (en) 1991-02-27
CA2021528C (en) 2001-09-11
ES2090061T3 (es) 1996-10-16
EP0409113A1 (de) 1991-01-23
AU638470B2 (en) 1993-07-01
JPH0372885A (ja) 1991-03-28
DE3923963A1 (de) 1991-01-31

Similar Documents

Publication Publication Date Title
AU5914590A (en) Muteins of human erythropoietin, the preparation thereof and the use thereof
DE3884427D1 (de) Polyquaternaere polysiloxan-polymere, deren herstellung und verwendung in kosmetischen zubereitungen.
ATE100283T1 (de) Nahrungsmittel, angereichert mit einem gehalt an nukleosiden und/oder nukleotiden und ihre herstellung.
ATE123030T1 (de) Piperidin-derivate, ihre herstellung und ihre verwendung.
DE69022595D1 (de) Herstellung von kohlefaser-halbfabrikaten.
GR852023B (el)
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE69232693D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
WO1994024160A3 (en) Erythropoietin muteins with enhanced activity
ATE4217T1 (de) Polyaetherverbindungen und ihre herstellung, entsprechende praeparate und die verwendung dieser produkte als heilmittel oder wachstumsfoerdernde mittel bei wiederkaeuern.
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE3681368D1 (de) Polymere produkte, zusammensetzungen, deren herstellung und verwendung.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE3870764D1 (de) Anilinophenylthioharnstoffe, -isothioharnstoffe und -carbodiimide, ihre herstellung und verwendung in der schaedlingsbekaempfung.
DE3868287D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3862766D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3865049D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
ATE235553T1 (de) Protein p100von menschlichem herpesvirus typ 6, die korrespondierenden dns squenzen, ihre herstellung und verwendung
DK145988A (da) Genteknologisk fremstillet 140 kd-antigen af plasmodium falciparum og dettes anvendelse
DE69005566D1 (de) Herstellung von para-phenylendiaminen.
DE3878988D1 (de) 1,2-di(4-isobutylphenyl)aethylen, dessen herstellung und verwendung als zwischenprodukt.
DE3868104D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3872161D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE59009879D1 (de) Reaktivfarbstoffe, deren Herstellung und Verwendung.
DE59003728D1 (de) 4-Aryl-2-halogenimidazol-5-carbonsäureester, ihre Herstellung und Verwendung.